Strategies for control of trachoma:: observational study with quantitative PCR

被引:178
作者
Solomon, AW
Holland, MJ
Burton, MJ
West, SK
Alexander, NDE
Aguirre, A
Massae, PA
Mkocha, H
Muñoz, B
Johnson, GJ
Peeling, RW
Bailey, RL
Foster, A
Mabey, DCW
机构
[1] Univ London London Sch Hyg & Trop Med, Clin Res Unit, London WC1E 7HT, England
[2] Tumaini Univ, Kilimanjaro Christian Med Coll, Moshi, Tanzania
[3] Huruma Hosp, Rombo Dist, Tanzania
[4] MRC Labs, Fajara, Gambia
[5] Johns Hopkins Univ, Dana Ctr Prevent Ophthalmol, Baltimore, MD USA
[6] Kongwa Trachoma Project, Kongwa, Tanzania
[7] WHO, Special Programme Res & Training Trop Dis, CH-1211 Geneva, Switzerland
[8] Hlth Canada, Natl Microbiol Lab, Winnipeg, MB, Canada
基金
英国惠康基金;
关键词
D O I
10.1016/S0140-6736(03)13909-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Antibiotics are an important part of WHO's strategy to eliminate trachoma as a blinding disease by 2020. At present, who needs to be treated is unclear. We aimed to establish the burden of ocular Chlamydia trachomatis in three trachoma-endemic communities in Tanzania and The Gambia with real-time quantitative PCR. Methods Conjunctival swabs were obtained at examination from 3146 individuals. Swabs were first tested by the qualitative Amplicor PCR, which is known to be highly sensitive. In positive samples, the number of copies of omp1 (a single-copy C trachomatis gene) was measured by quantitative PCR. Findings Children had the highest ocular loads of C trachomatis, although the amount of pooling in young age groups was less striking at the site with the lowest trachoma frequency. Individuals with intense inflammatory trachoma had higher loads than did those with other conjunctival signs. At the site with the highest prevalence of trachoma, 48 of 93 (52%) individuals with conjunctival scarring but no sign of active disease were positive for ocular chlamydiae. Interpretation Children younger than 10 years old, and those with intense inflammatory trachoma, probably represent the major source of ocular C trachomatis infection in endemic communities. Success of antibiotic distribution programmes could depend on these groups receiving effective treatment.
引用
收藏
页码:198 / 204
页数:7
相关论文
共 25 条
[1]   RANDOMIZED CONTROLLED TRIAL OF SINGLE-DOSE AZITHROMYCIN IN TREATMENT OF TRACHOMA [J].
BAILEY, RL ;
ARULLENDRAN, P ;
WHITTLE, HC ;
MABEY, DCW .
LANCET, 1993, 342 (8869) :453-456
[2]   DIAGNOSIS OF CHLAMYDIA-TRACHOMATIS EYE INFECTION IN TANZANIA BY POLYMERASE CHAIN-REACTION ENZYME-IMMUNOASSAY [J].
BOBO, L ;
MUNOZ, B ;
VISCIDI, R ;
QUINN, T ;
MKOCHA, H ;
WEST, S .
LANCET, 1991, 338 (8771) :847-850
[3]  
Bowman RJC, 2000, INVEST OPHTH VIS SCI, V41, P4074
[4]   Alterations in the conjunctival bacterial flora following a single dose of azithromycin in a trachoma endemic area [J].
Chern, KC ;
Shrestha, SK ;
Cevallos, V ;
Dhami, HL ;
Tiwari, P ;
Chern, L ;
Whitcher, JP ;
Lietman, TM .
BRITISH JOURNAL OF OPHTHALMOLOGY, 1999, 83 (12) :1332-1335
[5]  
Dawson ChandlerR., 1981, Guide to Trachoma Control in Programmes for the Prevention of Blindness
[6]   A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children [J].
Dawson, CR ;
Schachter, J ;
Sallam, S ;
Sheta, A ;
Rubinstein, RA ;
Washton, H .
CLINICAL INFECTIOUS DISEASES, 1997, 24 (03) :363-368
[7]  
Frick KD, 2001, B WORLD HEALTH ORGAN, V79, P201
[8]   Adverse and beneficial secondary effects of mass treatment with azithromycin to eliminate blindness due to trachoma in Nepal [J].
Fry, AM ;
Jha, HC ;
Lietman, TM ;
Chaudhary, JSP ;
Bhatta, RC ;
Elliott, J ;
Hyde, T ;
Schuchat, A ;
Gaynor, B ;
Dowell, SF .
CLINICAL INFECTIOUS DISEASES, 2002, 35 (04) :395-402
[9]  
Holm SO, 2001, B WORLD HEALTH ORGAN, V79, P194
[10]   A targeted, single-dose azithromycin strategy for trachoma [J].
Laming, AC ;
Currie, BJ ;
DiFrancesco, M ;
Taylor, HR ;
Mathews, JD .
MEDICAL JOURNAL OF AUSTRALIA, 2000, 172 (04) :163-166